4. WuXi Biologics (02269.hk) faces headwinds in the industry, but the company's strategy is clear: on one hand, it secures cutting-edge projects through technical collaborations, waiting for financing to recover; on the other hand, it continuously improves operational efficiency. I believe its global production capacity layout and diversified customer structure can help it withstand volatility in any single market and navigate through cycles.$WUXI BIO(02269.HK)
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
